Skip to main content
    E

    Evotec SE ADR (EVO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.42
    -0.01 (-0.35%)

    Market Cap: $478.00M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    28%(5/18)
    Avg Surprise
    -170.37%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.25
    Range$-0.25 - $-0.25
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.07-257.1%
    60d ago$-0.07-257.1%
    30d ago$-0.20-22.0%
    7d ago$-0.30+18.0%
    Current$-0.25
    Revenue Consensus
    $144M
    Range$144M - $144M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.97
    Range$-0.97 - $-0.97
    1 analysts
    Revenue Consensus
    $150M
    Range$127M - $230M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.97---
    Sep 26EST
    		-$-0.25---
    Jun 26
    Reported Aug 13
    		$-0.13$-0.04-225.00%Miss-8.3%
    Mar 26
    Reported Apr 8
    		$-0.34$-0.17-100.00%Miss-277.8%
    Dec 25
    Reported Dec 31
    		$0.04$0.07-35.71%Miss+139.1%
    Sep 25
    Reported Nov 5
    		$-0.12$-0.17+29.41%Beat-9.1%
    Jun 25
    Reported Aug 13
    		$-0.12$-0.13+7.69%Beat-33.3%
    Mar 25
    Reported Apr 17
    		$-0.09$-0.12+25.00%Beat-200.0%
    Dec 24
    Reported Dec 31
    		$-0.12$0.00N/AMiss-130.0%
    Sep 24
    Reported Nov 6
    		$-0.11$-0.12+8.33%Beat+8.3%
    Jun 24
    Reported Aug 14
    		$-0.09$-0.01-800.00%Miss-125.0%
    Mar 24
    Reported May 22
    		$-0.03$-0.03+0.00%Beat+57.1%
    Dec 23
    Reported Feb 26
    		$-0.05$-0.03-66.67%Miss+61.5%
    Sep 23
    Reported Nov 8
    		$-0.12$-0.05-140.00%Miss+7.7%
    Jun 23
    Reported Aug 29
    		$-0.04N/A-136.36%Miss+50.0%
    Mar 23
    Reported May 12
    		$-0.07N/A-133.33%Miss+65.0%
    Dec 22
    Reported Mar 29
    		$-0.13$0.10-230.00%Miss-18.2%
    Sep 22
    Reported Nov 9
    		$-0.13$0.15-186.67%Miss-106.9%
    Jun 22
    Reported Aug 11
    		$-0.08$0.03-366.67%Miss-109.1%
    Mar 22
    Reported Apr 12
    		$-0.20$0.06-433.33%Miss-125.8%
    Dec 21
    Reported Dec 31
    		$-0.11$0.06-283.33%Miss-2920.5%
    Sep 21
    Reported Nov 11
    		$1.88N/AN/ABeat+8723.9%
    Jun 21
    Reported Aug 11
    		$0.88N/AN/ABeat+714.9%
    Mar 21
    Reported May 11
    		$0.77N/AN/ABeat+210.5%
    Dec 20
    Reported Mar 25
    		$0.00N/AN/ABeat-96.6%
    Sep 20
    Reported Nov 12
    		$-0.02N/AN/ABeat-130.8%
    Jun 20
    Reported Aug 12
    		$-0.14N/AN/ABeat-1491.1%
    Mar 20
    Reported May 14
    		$0.25N/AN/ABeat+401.4%
    Dec 19
    Reported Mar 26
    		$0.12N/AN/ABeat-3.7%
    Sep 19
    Reported Nov 12
    		$0.07N/AN/ABeat-87.0%
    Jun 19
    Reported Aug 14
    		$-0.01N/AN/ABeat-103.9%
    Mar 19
    Reported Jun 29
    		$0.05N/AN/ABeat-13.9%
    Dec 18
    Reported Mar 28
    		$0.12N/AN/ABeat-26.8%
    Sep 18
    Reported Nov 13
    		$0.55N/AN/ABeat+1040.4%
    Jun 18
    Reported Aug 9
    		$0.23N/AN/ABeat+359.2%
    Mar 18
    Reported May 9
    		$0.06N/AN/ABeat-46.7%
    Dec 17
    Reported Mar 28
    		$0.16N/AN/ABeat+177.9%
    Sep 17
    Reported Nov 8
    		$0.05N/AN/ABeat-
    Jun 17
    Reported Aug 10
    		$0.05N/AN/ABeat-
    Mar 17
    Reported May 10
    		$0.11N/AN/ABeat-
    Dec 16
    Reported Mar 30
    		$0.06N/AN/ABeat-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    FrequencyMonthly
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio-2.61EV/EBITDAN/A
    Price/FCF-2.63xFCF Yield-37.99%
    Profitability
    Profit Margin-27.50%Operating Margin-62.30%
    ROE-26.10%ROIC-16.06%
    Financial Health
    Debt/Equity0.71xInterest Coverage-15.55x
    Current Ratio2.33xQuick Ratio2.21x
    Trading Statistics
    Beta1.27Avg Volume192.01K
    52-Week High$4.2752-Week Low$1.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.52
    SMA 20$1.55
    SMA 50$1.76
    SMA 200$2.63
    EMA 10$1.49
    EMA 20$1.56
    EMA 50$1.75
    EMA 200$2.46

    MACD

    Line: -0.09Signal: -0.08Hist: -0.01

    ADX

    ADX: 19.0+DI: 28.0-DI: 36.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down92.0
    PSAR$1.69

    Bollinger Bands

    Upper Band$1.75
    Lower Band$1.36
    %B Position2506%(Upper)
    Band Width0.15

    RSI (14-Day)

    Neutral
    35.2

    Momentum Oscillators

    Stoch %K16.7
    Stoch %D10.6
    Williams %R-77.5
    ROC (10d)-13.7%
    Momentum-0.23
    CCI (20d)-130.3
    MFI (14d)47.9

    Volatility Measures

    ATR (14d)$0.08(5.4%)
    StdDev (20d)0.10
    Hist Vol60.0%(High)

    Volume Flow

    VWAP$1.42
    OBV116.2K
    AD Line-2.6M
    CMF (20d)-0.271

    Volume Metrics

    Avg Vol (20d)208.9K
    Vol Ratio0.6x
    VWMA (20d)$1.57

    Pivot Points

    R3$1.54
    R2$1.51
    R1$1.47
    Pivot Point$1.44
    S1$1.40
    S2$1.37
    S3$1.33

    Advanced Oscillators

    TSI-28.85
    Ultimate Osc38.3
    KST-134.67

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$145.85M$159.22M$253.27M$163.89M$171.24M$199.98M$221.23M$184.89M$182.12M$208.73M$201.31M$196.28M
    Cost of Revenue$147.46M$160.81M$174.81M$163.95M$162.64M$172.75M$175.13M$166.61M$166.38M$173.97M$163.65M$158.45M
    Gross Profit$-1,606,159$-1,593,785$78.46M$-62,000$8.59M$27.23M$46.10M$18.28M$15.74M$34.76M$37.67M$37.82M
    Operating Expenses$50.37M$54.75M$216.06M$44.44M$36.37M$47.23M$213.10M$44.78M$120.35M$52.97M$49.21M$50.01M
    R&D$10.43M$10.25M$9.83M$8.71M$8.21M$10.76M$9.73M$11.87M$13.01M$16.24M$9.15M$17.50M
    SG&A$39.29M$43.79M$44.35M$42.31M$41.61M$47.70M$49.90M$46.39M$45.97M$45.94M$42.13M$39.29M
    Operating Income$-51,973,512$-56,348,643$37.21M$-44,502,000$-27,773,000$-20,008,000$8.13M$-26,493,000$-104,606,000$-18,207,000$-11,547,000$-12,187,000
    Interest Income$183,000$1.79M$1.16M$841,000$1.21M$1.22M$367,000$917,000$467,000$1.42M$1.10M$2.48M
    Interest Expense$3.02M$2.63M$3.76M$2.28M$6.00M$2.41M$4.42M$1.87M$2.74M$2.67M$3.18M$3.52M
    Income Before Tax$-48,916,724$-124,189,208$29.46M$-42,960,000$-43,419,000$-29,851,000$-15,866,000$-46,874,000$-85,409,001$-14,564,001$-24,025,000$-29,916,000
    Income Tax Expense$-1,495,354$-248,012$0$127,000$59,000$1.73M$0$-7,241,000$9.52M$6.11M$-7,895,000$9.04M
    Net Income$-47,421,370$-123,941,196$14.62M$-43,087,000$-43,478,000$-31,577,000$-40,839,000$-39,634,000$-94,932,000$-20,673,000$-16,131,000$-38,955,000
    EBITDA$-27,129,875$-97,352,021$33.22M$-17,643,000$-3,422,000$-27,444,000N/A$-19,698,000$-11,746,500$-437,500$2.98M$12.22M
    EBIT$-51,973,512$-121,563,732$33.22M$-42,960,000$-28,599,000$-11,449,000N/A$-45,008,000$-36,151,000$-18,208,000$-20,844,000$-12,175,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EVO

    News

    Evotec appoints Joanna Holbrook as chief scientific officer: Evotec stock pre-market at EUR 2.56

    Evotec has appointed Joanna Holbrook as its new chief scientific officer and management board member, effective November 1...

    ad-hoc-news.de•10/16/26•Somewhat-Bullish

    Evotec Appoints Joanna Holbrook as Chief Scientific Officer

    Evotec SE has appointed Dr. Joanna Holbrook as its new Chief Scientific Officer and Member of the Management Board, effective November 1...

    Contract Pharma•10/15/26•Bullish

    Mubadala Investment Co PJSC Exits Evotec SE (EVOTF) -- Shares Look 57% Undervalued on GF Value

    Mubadala Investment Co PJSC has fully divested its position in Evotec SE (EVOTF), selling all shares at $3.325 each. Despite Evotec SE appearing 57% undervalued according to GF Value...

    GuruFocus•10/15/26•Neutral

    Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

    Evotec SE has published a voting rights announcement indicating that the Government of Abu Dhabi's indirect stake in the company, held through Mubadala Investment Company PJSC...

    TradingView•10/15/26•Neutral

    Evotec SE (EVT) Reports Major Holdings Notification

    Evotec SE (EVT) has issued a major holdings notification under German law, indicating an indirect stake held by Mubadala Investment Company PJSC...

    TradingView•10/15/26•Neutral

    EVO Valuation and Fair Value

    P/E
    -2.6x
    Forward P/E
    19.6x
    P/FCF
    -2.6x
    PEG
    1.4x
    P/B
    0.7x
    See GNG's fair value

    EVO Profitability: Margins, ROIC and FCF

    Gross margin
    10.5%
    Operating margin
    -62.3%
    Net margin
    -27.5%
    ROIC
    -16.1%
    ROE
    -26.1%
    FCF margin
    -19.9%
    FCF yield
    -38.0%

    EVO Competitors

    CompanyTicker
    Regenxbio IncRGNX
    XOMA CorpXOMA
    Sight Sciences IncSGHT
    Senseonics Holdings, Inc. Common StockSENS
    Evolus IncEOLS
    AngioDynamics IncANGO
    Tactile Systems Technology IncTCMD
    Tilray IncTLRY

    Sector: Healthcare

    EVO Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    1
    Buy
    1
    Hold
    1
    Sell
    0
    Strong Sell
    0

    EVO Bull Case vs Bear Case

    Bear case

    • EVO has a -27.5% net profit margin.
    • EVO's quarterly revenue changed -16.2% year over year.

    EVO Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -41.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.25
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    EVO Dividend

    Forward yield
    0.0%

    Frequently Asked Questions About EVO

    Does EVO pay dividends?

    Evotec SE ADR (EVO) has a dividend payment track record. See the EVO dividend history page for its current payment status, TTM yield, and recorded payments.

    What is EVO's market cap?

    Evotec SE ADR (EVO) has a market capitalization of $478.00M with a current stock price of $1.42.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In